New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. The lead ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s ...

Developing brand new drugs is a long ... buying smaller biotechs developing drugs in major markets such as obesity and oncology. 2025's top drug targets Obesity is positioned to be biopharma's ...

(Bloomberg) -- A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the ...

Overall, average healthcare costs increased 46% over two years for patients trying GLP-1 drugs for obesity, from $12,695 to $18,507. The Congressional Budget Office states that there does not ...

The drug-maker’s own target was higher and market expectation have risen sharply in the past few years. In a new study, an experimental obesity drug from Novo Nordisk, CagriSema allowed people ...

In this photo is a Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. (Photographer: Shelby Knowles/Bloomberg) The anti-obesity drug Zepbound ...